Deferasirox - Novartis

Drug Profile

Deferasirox - Novartis

Alternative Names: CGP-72670; Deferasirox; Exjade; ICL-670; ICL-670A; Jadenu

Latest Information Update: 26 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; University Hospital Grenoble
  • Class Antianaemics; Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents; Cytochrome P 450 cyp2c8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase II Myelodysplastic syndromes; Thalassaemia
  • Discontinued Malaria

Most Recent Events

  • 21 May 2018 Phase II development in Myelodysbastic syndromes (Monotherapy) is ongoing (NCT00940602)
  • 27 Feb 2018 Novartis completes the phase II TELESTO trial in Iron overload (transfusion related) and Myelodysplastic syndromes (Monotherapy) in the UK, US, Thailand, Switzerland, Russia, New Zealand, Romania, Mexico, Malaysia, Italy, Hong Kong, Greece, Denmark, China, Canada, Bulgaria and Australia (NCT00940602)
  • 20 Feb 2018 Phase-II clinical trials in Myelodysplastic syndromes (Second-line therapy or greater, In adults, In the elderly) in France (PO) (NCT03387475)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top